- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 217/14 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
Patent holdings for IPC class C07D 217/14
Total number of patents in this class: 154
10-year publication summary
|
15
|
8
|
11
|
18
|
6
|
9
|
11
|
8
|
6
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Ardelyx, Inc. | 113 |
8 |
| Novartis AG | 10883 |
6 |
| Merck Patent GmbH | 5850 |
6 |
| Ferro Therapeutics, Inc. | 13 |
5 |
| Tongli Biomedical Co., Ltd | 31 |
4 |
| Bristol-myers Squibb Company | 4875 |
3 |
| LG Chem, Ltd. | 17564 |
3 |
| The General Hospital Corporation | 4710 |
3 |
| Astellas Pharma Inc. | 1086 |
3 |
| Blueprint Medicines Corporation | 232 |
3 |
| Eli Lilly and Company | 3825 |
3 |
| Omeros Corporation | 307 |
3 |
| Epiodyne, Inc. | 7 |
3 |
| The Regents of the University of California | 19839 |
2 |
| Takeda Pharmaceutical Company Limited | 2708 |
2 |
| Actelion Pharmaceuticals Ltd | 533 |
2 |
| Arena Pharmaceuticals, Inc. | 367 |
2 |
| Daito Chemix Corporation | 11 |
2 |
| Enanta Pharmaceuticals, Inc. | 428 |
2 |
| Figene, LLC | 163 |
2 |
| Other owners | 87 |